239 304

Cited 21 times in

Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis

Authors
 Seock-Ah Im  ;  Binghe Xu  ;  Wei Li  ;  Mark Robson  ;  Quchang Ouyang  ;  Dah-Cherng Yeh  ;  Hiroji Iwata  ;  Yeon Hee Park  ;  Joo Hyuk Sohn  ;  Ling-Ming Tseng  ;  Carsten Goessl  ;  Wenting Wu  ;  Norikazu Masuda 
Citation
 SCIENTIFIC REPORTS, Vol.10(1) : 8753, 2020-05 
Journal Title
SCIENTIFIC REPORTS
Issue Date
2020-05
MeSH
Adult ; Aged ; Antineoplastic Agents / therapeutic use* ; Asian Continental Ancestry Group ; Breast Neoplasms / drug therapy* ; Breast Neoplasms / genetics ; Capecitabine / therapeutic use ; Carcinoma / drug therapy ; Carcinoma / genetics ; Carcinoma / secondary* ; Female ; Furans / therapeutic use ; Gastrointestinal Diseases / chemically induced ; Genes, BRCA1* ; Genes, BRCA2* ; Genes, erbB-2 ; Germ-Line Mutation ; Hematologic Diseases / chemically induced ; Humans ; Kaplan-Meier Estimate ; Ketones / therapeutic use ; Middle Aged ; Phthalazines / adverse effects ; Phthalazines / therapeutic use* ; Piperazines / adverse effects ; Piperazines / therapeutic use* ; Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use* ; Progression-Free Survival ; Single-Blind Method ; Vinorelbine / therapeutic use
Abstract
The OlympiAD Phase III study (NCT02000622) established the clinical benefits of olaparib tablet monotherapy (300 mg twice daily) over chemotherapy treatment of physician's choice (TPC) in patients with a germline BRCA1/2 mutation (gBRCAm) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who had received ≤2 chemotherapy lines in the metastatic setting. Here, we report pre-specified analyses of data from Asian (China, Japan, Korea and Taiwan) patients in the study. All patients were randomized 2:1 to olaparib tablets (300 mg twice daily) or single-agent chemotherapy TPC (21-day cycles of either capecitabine, eribulin or vinorelbine). The primary endpoint was progression-free survival assessed by blinded independent central review. The prevalence of gBRCAm in the OlympiAD Asian subgroup screened for study recruitment was 13.5%. Patient demographics and disease characteristics of the Asian subgroup (87/302 patients) were generally well balanced between treatment arms. Asian patients in the olaparib arm achieved longer median progression-free survival, assessed by blinded independent central review, versus the chemotherapy TPC arm (5.7 vs 4.2 months; HR = 0.53 [95% CI: 0.29-0.97]), which was consistent with findings in the global OlympiAD study population. Findings on secondary efficacy and safety/tolerability outcome measures in Asian patients were also similar to those observed in the global OlympiAD study population. The OlympiAD study was not powered to detect race-related differences between treatment groups; however, the consistency of our findings with the global OlympiAD study population suggests that previously reported findings are generalizable to Asian patients.
Files in This Item:
T999202215.pdf Download
DOI
10.1038/s41598-020-63033-4
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers
Yonsei Authors
Sohn, Joo Hyuk(손주혁) ORCID logo https://orcid.org/0000-0002-2303-2764
Choi, Young Chul(최영철) ORCID logo https://orcid.org/0000-0001-5525-6861
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/184953
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links